GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (STU:JSS) » Definitions » Cyclically Adjusted Revenue per Share

Nxera Pharma Co (STU:JSS) Cyclically Adjusted Revenue per Share : €0.91 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Nxera Pharma Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nxera Pharma Co's adjusted revenue per share for the three months ended in Mar. 2024 was €0.317. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.91 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Nxera Pharma Co's average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nxera Pharma Co was 15.90% per year. The lowest was 15.40% per year. And the median was 15.70% per year.

As of today (2024-06-14), Nxera Pharma Co's current stock price is €8.95. Nxera Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.91. Nxera Pharma Co's Cyclically Adjusted PS Ratio of today is 9.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nxera Pharma Co was 42.01. The lowest was 8.60. And the median was 17.48.


Nxera Pharma Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Nxera Pharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Cyclically Adjusted Revenue per Share Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.75 0.87 0.94 0.94

Nxera Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.86 0.87 0.94 0.91

Competitive Comparison of Nxera Pharma Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted PS Ratio falls into.



Nxera Pharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nxera Pharma Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.317/107.2000*107.2000
=0.317

Current CPI (Mar. 2024) = 107.2000.

Nxera Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.031 98.000 0.034
201409 0.043 98.500 0.047
201412 0.047 97.900 0.051
201503 0.375 97.900 0.411
201506 0.075 98.400 0.082
201509 0.257 98.500 0.280
201512 0.593 98.100 0.648
201603 0.048 97.900 0.053
201606 1.879 98.100 2.053
201609 0.098 98.000 0.107
201612 0.147 98.400 0.160
201703 0.228 98.100 0.249
201706 0.329 98.500 0.358
201709 0.282 98.800 0.306
201712 0.106 99.400 0.114
201803 0.065 99.200 0.070
201806 0.085 99.200 0.092
201809 0.097 99.900 0.104
201812 0.110 99.700 0.118
201903 0.326 99.700 0.351
201906 0.206 99.800 0.221
201909 0.294 100.100 0.315
201912 0.207 100.500 0.221
202003 0.121 100.300 0.129
202006 0.145 99.900 0.156
202009 0.189 99.900 0.203
202012 0.464 99.300 0.501
202103 0.116 99.900 0.124
202106 0.178 99.500 0.192
202109 0.044 100.100 0.047
202112 1.260 100.100 1.349
202203 0.105 101.100 0.111
202206 0.116 101.800 0.122
202209 0.527 103.100 0.548
202212 0.569 104.100 0.586
202303 0.080 104.400 0.082
202306 0.096 105.200 0.098
202309 0.256 106.200 0.258
202312 0.555 106.800 0.557
202403 0.317 107.200 0.317

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Nxera Pharma Co  (STU:JSS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nxera Pharma Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8.95/0.91
=9.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nxera Pharma Co was 42.01. The lowest was 8.60. And the median was 17.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nxera Pharma Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (STU:JSS) Business Description

Industry
Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (STU:JSS) Headlines

No Headlines